Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ h( h8 K' k6 P% i% ^3 U- F4 @% ^NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 9 ?% I3 a; C/ P# Y a
+ Author Affiliations
) Y* g2 n9 f* Y" ?- _6 u1 i2 {5 R. I- N9 P; _
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
0 E/ O' l. i. }4 p$ E2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) s; E R5 d& @1 e3 S5 K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' }6 h0 R" \- O8 Y) x4 [ B8 t4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 j, i" X# \- Z- Q. v" L1 H5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
3 y1 S: I0 `) [& D6 I* m9 _6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ; J. N) a% r: u$ o# p/ u
7Kinki University School of Medicine, Osaka 589-8511, Japan
) b+ Y7 U4 E7 t8Izumi Municipal Hospital, Osaka 594-0071, Japan 5 D- l2 D. Q/ c4 L$ B6 b3 w7 G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
G- F0 u+ Y' ?7 z4 [3 O8 bCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp " }7 V4 y0 X4 ^6 c: e( k+ u3 b
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ Y9 J4 B. F% D1 N* H( v! }% u6 G. u M! z9 V' N
|